<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182321</url>
  </required_header>
  <id_info>
    <org_study_id>960-2019-84</org_study_id>
    <nct_id>NCT04182321</nct_id>
  </id_info>
  <brief_title>Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B</brief_title>
  <official_title>Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B: A Single-Center, Randomized, Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu-Sheng Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, placebo-controlled pilot study to assess the efficacy&#xD;
      and safety of adding Metformin to the standard treatment for patients with HBeAg-positive&#xD;
      chronic hepatitis B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, placebo-controlled pilot study to assess the efficacy&#xD;
      and safety of adding Metformin to the standard treatment for patients with HBeAg-positive&#xD;
      chronic hepatitis B. Sixty subjects who meet the eligibility criteria will be randomized to&#xD;
      the experimental arm and comparator arm according to a 1:1 ratio. The participants in the&#xD;
      experimental arm will be treated with Metformin (sustained release tablet, 1000 mg, once a&#xD;
      day(QD), 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment). The participants in&#xD;
      the comparator arm will be treated with Placebo (two tablets, QD, 24 weeks) and Entecavir&#xD;
      (tablet, 0.5 mg, QD, ongoing treatment). The primary endpoint for efficacy assessment is the&#xD;
      cumulative rate of HBsAg loss at week 36 after enrollment; the secondary endpoint for&#xD;
      efficacy assessment is the decrease in quantitative HBsAg from the baseline at week 36 after&#xD;
      enrollment. The secondary endpoint for safety assessment is the cumulative incidence of&#xD;
      adverse events at week 36 after enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">July 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Rate of HBsAg Loss</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>HBsAg Loss is defined as disappearance of HBsAg in patients with chronic hepatitis B during treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Quantitative HBsAg from the Baseline</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>Quantitative HBsAg is a quantitative indicator reflecting HBsAg level in patients with chronic hepatitis B during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Adverse Events</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered study drug and that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adding Metformin to the standard treatment for patients with HBeAg-negative chronic hepatitis B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The standard treatment for patients with HBeAg-negative chronic hepatitis B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin &amp; Entecavir</intervention_name>
    <description>Metformin (sustained release tablet, 1000 mg, QD, 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment)</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo &amp; Entecavir</intervention_name>
    <description>Placebo (two tablets, QD, 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment)</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HBeAg negative chronic hepatitis B&#xD;
&#xD;
          -  Ongoing treatment with Entecavir for more than 12 months&#xD;
&#xD;
          -  HBV DNA &lt; 500 IU/mL&#xD;
&#xD;
          -  Quantitative HBsAg &lt; 1000 IU/mL&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &lt; 2 Ã— upper limit of normal (ULN)&#xD;
&#xD;
          -  Agreed to take contraceptive measures during participation for women of a fertile age&#xD;
&#xD;
          -  Agreed not to engage in other clinical trials during participation&#xD;
&#xD;
          -  Understood and signed the informed consent form before taking any steps related to&#xD;
             this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Alcoholic liver disease&#xD;
&#xD;
          -  Drug-induced liver damage&#xD;
&#xD;
          -  Autoimmune liver disease&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Liver cancer&#xD;
&#xD;
          -  Liver transplantation&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Other conditions judged by investigators unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Sheng Wang</last_name>
    <role>Study Chair</role>
    <affiliation>The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 960th Hospital of Chinese PLA Joint Logistics Support Force (Jinan Military General Hospital)</name>
      <address>
        <city>Tai'an</city>
        <state>Shandong</state>
        <zip>271000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing 302 Hospital</investigator_affiliation>
    <investigator_full_name>Fu-Sheng Wang</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Entecavir</keyword>
  <keyword>hepatitis B virus (HBV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

